Perry Calias

Current

• Owner at DC Polymers
• Sr. Director and Head of Nonclinical Development at Shire HGT

Past

• Director Drug Discovery at Shire Therapeutics
• Vice President Research and Development at EyeGate Pharmaceuticals
• Sr. Director Drug Delivery and Chemistry at Eyetech Pharmaceuticals

see less...

Education

• Tufts University
• Suffolk University

Recommended

1 person has recommended Perry

Connections

158 connections

Industry

Biotechnology

Perry Calias’s Summary

Dynamic, self-motivated manager with 11 years industry experience working in multidisciplinary environments.
• Proven record of innovation and versatility in the areas of ocular drug delivery,
biopolymers, oligonucleotides, polysaccharide synthesis and assay
development
• Major strengths include proven leadership qualities, exceptional interpersonal
skills, and demonstrated experience successfully directing multiple projects
from conception through Phase 1
• Negotiated multiple research collaborations and license agreements
• Directed the design, build-out, staffing, and operations of three research
facilities
• Successfully raised $12M in a series B round of financing

Perry Calias’s Experience

• Owner

  DC Polymers

  (Biotechnology industry)

  Currently holds this position

• Sr. Director and Head of Nonclinical Development

  Shire HGT

  (Public Company; Biotechnology industry)

  August 2008 — Present (1 year)

• Director Drug Discovery

  Shire Therapeutics

  (Biotechnology industry)

  June 2007 — August 2008 (1 year 3 months)

• Vice President Research and Development

  EyeGate Pharmaceuticals

  (Privately Held; Biotechnology industry)

  January 2006 — June 2007 (1 year 6 months)

  • Prepared and presented the scientific strategy for a successful series B fund
  raising of $12M in a 7 month period.
  • Developed the scientific portfolio and wrote the due diligence package used for
  Venture Capital audits.
  • Established the Waltham Research Facility and developed the core team,
  consisting of 12 employees, ranging from EH&S, Quality, Animal Husbandry,
  Microscopy, Engineering, Formulations, Finance, and IT.
  • Managed the transfer and repositioning of the intellectual property from France to
  a U.S. law firm.
  • Developed the research goals and identified the appropriate formulation to enable
  an IND filing for the iontophoretic delivery of steroids for Severe Uveitis and to
  enable ex-US clinical studies in Uveitis and DME.
  • Developed and implemented the research strategy to enable the ocular delivery of
  proteins, oligonucleotides, steroids, and colloidal systems utilizing iontophoresis.

• Sr. Director Drug Delivery and Chemistry

  Eyetech Pharmaceuticals

  (Public Company; 201-500 employees; EYET; Biotechnology industry)

  January 2002 — December 2005 (4 years)

  • Directed 8 internal scientists and two external CRO’s in developing an intravitreal
  PLG-Aptamer microsphere formulation with a target release profile of 4.5-6
  months.
  • Completed initial PK studies, negotiated a development agreement and initiated a
  project plan for a 2008 IND filing of an encapsulated aptamer formulation for the
  treatment of Age-Related Macular Degeneration.
  • Managed the development of a novel reconstitution device for small volume
  (100uL) resuspension of a lyophilized microsphere formulation.
  • Identified, negotiated, and managed 5 feasibility studies investigating the ocular
  delivery of aptamers utilizing microspheres, polymeric depots, liposomal
  formulations, and iontophoresis.
  • Directed the selection, design, and build out of the Lexington Research Facility
  (46,000 ft2), including a 5,000 ft2 animal facility.

Perry Calias’s Education

• Tufts University

  Ph.D. , Bioorganic Chemistry , 1991 — 1996

• Suffolk University

  B.S. , Marine Biology/Chemistry , 1985 — 1989

Additional Information

Perry Calias’s Groups:

Masons

•    BIO International Convention

Perry Calias’s Contact Settings

Interested In:

• career opportunities
• consulting offers
• new ventures
• job inquiries
• expertise requests
• business deals
• reference requests
• getting back in touch